These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8752253)

  • 21. [In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost].
    de Mouzon J; Allavena E; Schmitt C; Frappé M
    Gynecol Obstet Fertil; 2004 Jun; 32(6):508-18. PubMed ID: 15217566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of seven IVF strategies: results of a Markov decision-analytic model.
    Fiddelers AA; Dirksen CD; Dumoulin JC; van Montfoort AP; Land JA; Janssen JM; Evers JL; Severens JL
    Hum Reprod; 2009 Jul; 24(7):1648-55. PubMed ID: 19318703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of in vitro fertilization.
    Goldfarb JM; Austin C; Lisbona H; Peskin B; Clapp M
    Obstet Gynecol; 1996 Jan; 87(1):18-21. PubMed ID: 8532258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of oocyte cryostorage for the practice of oocyte donation.
    Mertes H; Pennings G; Dondorp W; de Wert G
    Hum Reprod; 2012 Oct; 27(10):2886-93. PubMed ID: 22802093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health care costs resulting from IVF: prenatal and neonatal periods.
    Koivurova S; Hartikainen AL; Gissler M; Hemminki E; Klemetti R; Järvelin MR
    Hum Reprod; 2004 Dec; 19(12):2798-805. PubMed ID: 15388684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural in vitro fertilization cycles.
    Ubaldi F; Rienzi L; Ferrero S; Baroni E; Iacobelli M; Sapienza F; Minasi MG; Cobellis L; Romano S; Scarselli F; Greco E
    Ann N Y Acad Sci; 2004 Dec; 1034():245-51. PubMed ID: 15731316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience employing co-culture of human embryos with autologous human endometrial epithelial cells.
    Rubio C; Simón C; Mercader A; Garcia-Velasco J; Remohí J; Pellicer A
    Hum Reprod; 2000 Dec; 15 Suppl 6():31-8. PubMed ID: 11261481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The debate continues. Donor oocyte compensation.
    Sauer MV
    Fertil Steril; 1999 Jul; 72(1):182-3. PubMed ID: 10428174
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical implication and frequency of the incidental finding of endometriosis during oocyte retrieval].
    Ruiz Anguas J; Carballo Mondragón E; Anta Jaen E; Durán Monterrosas L; Kably Ambe A
    Ginecol Obstet Mex; 2007 Mar; 75(3):121-6. PubMed ID: 17547085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The singleton, term gestation, and live birth rate per cycle initiated: a 1-year experience in in vitro fertilization cycles with native and donated oocytes.
    Bellver J; Albert C; Soares SR; Alvarez C; Pellicer A
    Fertil Steril; 2005 May; 83(5):1404-9. PubMed ID: 15866576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro fertilization (IVF) versus gonadotropins followed by IVF as treatment for primary infertility: a cost-based decision analysis.
    Kansal-Kalra S; Milad MP; Grobman WA
    Fertil Steril; 2005 Sep; 84(3):600-4. PubMed ID: 16169391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormonal therapy for the synchronization between donor and recipient in an oocyte donation and surrogacy fertilization in vitro-embryo transfer program].
    Zhang L; Chen G; Liu P
    Zhonghua Fu Chan Ke Za Zhi; 1996 Aug; 31(8):486-9. PubMed ID: 9275443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In-vitro fertilization in economic perspective].
    Haan G; van Steen RH
    Ned Tijdschr Geneeskd; 1990 Oct; 134(43):2098-102. PubMed ID: 2122265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost of transferring one through five embryos per in vitro fertilization cycle from various payor perspectives.
    Little SE; Ratcliffe J; Caughey AB
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):593-601. PubMed ID: 16946220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Health economic consequences of the choice of follicle stimulating hormone alternatives in IVF treatment].
    Poulsen PB; Højgaard A; Quartarolo JP
    Ugeskr Laeger; 2007 Apr; 169(14):1313-7. PubMed ID: 17437694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ["Initial results of the first ambulatory program for in vitro fertilization in Mexico"].
    Kably Ambe A; Barrón Vallejo J; Carballo Mondragón E; Anta Jaen E
    Ginecol Obstet Mex; 1997 Jun; 65():229-34. PubMed ID: 9273332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Can one authorize oocyte donation in the Grand Duchy of Luxembourg?].
    Arendt J
    Bull Soc Sci Med Grand Duche Luxemb; 2012; (1):21-31. PubMed ID: 22822560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The debate continues. Donor oocyte compensation.
    Friedman S
    Fertil Steril; 1999 Jul; 72(1):182-3. PubMed ID: 10428173
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of multiple cycles in oocyte donors.
    Jain A; Robins JC; Williams DB; Thomas MA
    Am J Obstet Gynecol; 2005 May; 192(5):1382-4. PubMed ID: 15902115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of myomectomy on the outcome of assisted reproductive technologies.
    Surrey ES; Minjarez DA; Stevens JM; Schoolcraft WB
    Fertil Steril; 2005 May; 83(5):1473-9. PubMed ID: 15866587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.